Evidence · Journal club · continued
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove posts 91–91
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
This topic was referenced in
- About the Journal club categoryEvidence › Journal club · 6 replies
- Follow-up: Journal club: orforglipron phase 2 and the non-peptide questionEvidence › Journal club · 91 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: PIONEER 6 as a safety trial
Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it before posting; the…
|
+14 | 18 | 262 | 5mo |
|
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022) and finding…
|
+2 | 6 | 39k | 12mo |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURPASS-2 ( N Engl J Med ,…
|
+70 | 76 | 4.8k | 15h |
|
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not…
|
2 | 329 | 21h | |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…
|
+110 | 122 | 46k | 1d |
Related topics — sharing the tags number needed to treat, risk of bias, journal club
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
|
2 | 7.5k | 2mo | |
|
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please read…
|
2 | 8.9k | 4mo | |
|
Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…
|
+18 | 22 | 37k | 8mo |
|
Non-inferiority margins: how they are chosen and how they are abused
Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with…
|
+42 | 46 | 10k | 5mo |
|
Second pass at: Cagrilintide molecular characteristics and analytical considerations
On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019).…
|
4 | 5k | 21d |